Navigation Links
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Date:3/10/2011

mber 31, 2010. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements This news release includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties.  These include, among others, risks and timing associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that are superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2010. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.Contactssanofi-aventis:Megan HumphreyOncology Division CommunicationsTel: 1 (617) 679-5637E-mail: megan.humphrey@sanofi-aventis.comMarisol PeronCorporate Media RelationsTel: +33 (0) 1 53 77 45 02; Mobile: +33 (0) 6 0
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Sanofi-aventis Stands Behind the Safety of Lantus(R)
4. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
5. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
6. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
7. Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
8. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
9. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
10. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
11. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... SAN DIEGO , July 30, 2014 /PRNewswire/ ... held biotech company that designs and develops novel ... management of cancer, announced today the completion of ... The financing included new investors RusnanoMedInvest (RMI) and ... Fund, and Pfizer Venture Investments, as well as ...
(Date:7/30/2014)... , July 30, 2014 ... and CUDA programming expertise to big data, aerospace ... eInfochips, a leading engineering R&D services ... to develop NVIDIA GPU-powered solutions for aerospace ... high-performance computing (HPC), industrial , and ...
(Date:7/29/2014)... CAMBRIDGE, Mass. and HERZLIYA PITUACH, ... Inc. (OTCQX and NASDAQ OMX First North Premier, ... announces today that it has initiated the screening of ... trial exploring the safety and efficacy of bertilimumab in ... open-label trial will enroll 10-15 patients who will receive ...
Breaking Medicine Technology:Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5
(Date:7/31/2014)... National non-profit World T.E.A.M. Sports’ annual Adventure ... 12-14, following two years in the high Colorado Plateau. ... and able-bodied athletes competing together in an inclusive outdoor ... experienced adventure athletes. , Hosted at the rustic ... River in the rugged Gore Mountains northwest of Vail, ...
(Date:7/31/2014)... July 31, 2014 In its latest blog ... and believes that having family close by during a stay ... not the process is successful, is looking at 10 tips ... , “Addiction recovery is a lifelong process, and one ... be committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
(Date:7/31/2014)... When guests shop CVS, they’ll find many ... Shea Moisture. And now CVS is adding another acclaimed brand ... 1, guests will find G Natural products in CVS stores ... CEO Roger Gore was inspired to start G’Natural Herbal Products ... developing a receding hairline; he tried many products on the ...
(Date:7/30/2014)... (PRWEB) July 31, 2014 Push to ... ninth annual national “Shop For A Cause” charity shopping ... Cause” is a unique one-day-only shopping event created to ... more than $44 million for charities across the country ... by purchasing shopping passes from Push to Walk now. ...
(Date:7/30/2014)... July 31, 2014 Responding to ... environment more responsive to an increasingly diverse patient ... experience and scholarly expertise to the publication of ... care professions: "Diversity and Cultural Competence in Health ... L. Dreachslin, PhD, a professor in the Management ...
Breaking Medicine News(10 mins):Health News:World T.E.A.M. Sports’ Adventure Team Challenge Returns to Colorado’s High Country 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge Returns to Colorado’s High Country 3Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:CVS Caremark Adds New, Natural Acclaimed Hair Care Line to its Beauty Roster 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 3Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 3
... , , , LOUISVILLE, Ky., July ... regional provider of home health nursing services, announced today that it will ... on Wednesday, August 5, 2009, before the market open. , , ... 11:00 a.m. ET on August 5, 2009, and will be hosted by ...
... , WASHINGTON, July 31 Last ... Democratic leadership,s health care bill, H.R. 3200, that would specifically include ... of this bill. Family Research Council Action President Tony Perkins had ... Energy and Commerce Committee mark up: , , ...
... , , , , ... , HARRISBURG, Pa., July 31 Department of ... observance of National Immunization Awareness Month. , , ... sure you and your family are up-to-date on these immunizations is ...
... , , , ... statement by Jim O,Hara, Director, Produce Safety Project: , , ... the safety of fresh produce. The proposed guidance documents put out ... that the agency will finalize these documents quickly. We also look ...
... linked to headache, researchers explain , FRIDAY, July 31 ... cosmetic surgery, Michelle Cramer has now lost most of ... her frown lines. , Cramer, a graphics illustrator in ... close to a decade until she had surgery to ...
... , , , ABA program ... CALDWELL, N.J., July 31 Caldwell College will launch ... Analysis (ABA), a well developed scientific discipline that is best known ... disorder. Caldwell,s program was recently approved by the New Jersey ...
Cached Medicine News:Health News:Almost Family, Inc. to Report Second Quarter 2009 Financial Results on August 5, 2009 2Health News:House Measure Proves Healthcare Legislation Will Fund Abortion, Says Family Research Council Action 2Health News:Pennsylvania Secretary of Health Urges Pennsylvanians to Get Immunized 2Health News:Pennsylvania Secretary of Health Urges Pennsylvanians to Get Immunized 3Health News:Plastic Surgery Technique Might Ease Migraines 2Health News:Plastic Surgery Technique Might Ease Migraines 3Health News:Caldwell College Receives Approval to Launch First Ph.D. for Applied Behavior Analysis-Autism Treatment in New Jersey 2
... Merit Medical is pleased to offer ... The pre-coated, high-performance, InQwire guide wire ... is very lubricious and can help ... available in a wide range of ...
... The MULTI-LINK VISION Coronary Stent System ... of cobalt chromium stents. Cobalt chromium is ... so a cobalt chromium stent can have ... stainless steel stent with struts that are ...
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary ... antiproliferative drug, called "sirolimus", a ... stent delivery platform. Upon placement, ... wall and impedes the process ...
Medicine Products: